Ae23-Translational and Integrative Oncology (Emerging)
Oncology / IBS-Ae23 / Emerging
The group carries out clinical, translational and integrative cancer research tasks with the main objective of facilitating the transition from basic research into clinical applications that benefit health. This translational medicine is aimed at amortizing the effort devoted to basic research for economic and medical benefit.
Research lines
- Translational Oncology
- Integrative Oncology
CARMEN GRIÑAN LISON
SANDRA REDONDO SANCHEZ
NOELIA FERNANDEZ GUERRERO
CRISTINA GOMEZ ALVAREZ
Laura Campos Perez
VANESSA GABRIELA JERVIZ GUIDE
JESUS CALAHORRA GARCIA-MORENO
CRISTINA PRIETO PRIETO
MARTA LEGEREN ALVAREZ
PATRICIA MARIA RODRIGUEZ GOMEZ
SATURN OF KINGS LARTATEGUI
SILVIA SEQUERO LOPEZ
TANIA GALLART ARAGON
CARLOS JOSE RODRIGUEZ GONZALEZ
MAIN SERGIO GRANADOS
ISABEL BLANCAS LOPEZ-BARAJAS
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
ECLINICAL MEDICINE, 2024;
FI: 9,6; D1
Modeling low-intensity ultrasound mechanotherapy impact on growing cancer stem cells
MATHEMATICS AND COMPUTERS IN SIMULATION, 2024;
FI: 4,4; D1
Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
BIOMEDICINE & PHARMACOTHERAPY, 2024;
FI: 6,9; D1
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
MOLECULAR CANCER, 2024;
FI: 27,7; D1
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Lung Cancer, 2024;
FI: 4,5; Q1
Early increase in tamoxifen dose in CYP2D6 poor metabolizer breast cancer patients and survival: A propensity score matching analysis
BREAST, 2023;
FI: 3,9; Q1
Discovery of a synthetic taiwaniaquinoid with potent in vitro and in vivo antitumor activity against breast cancer cells
BIOMEDICINE & PHARMACOTHERAPY, 2023;
FI: 7,5; Q1
TGFß Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023;
FI: 9,2; Q1
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023)
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023;
FI: 3,4; Q3
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023;
FI: 3,4; Q3
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
ANNALS OF ONCOLOGY, 2022;
FI: 51,769; D1
EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumor colonization
ONCOGENE, 2022;
FI: 8,756; D1
Caffeine and Chlorogenic Acid Combination Attenuate Early-Stage Chemically Induced Colon Carcinogenesis in Mice: Involvement of oncomiR miR-21a-5p
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
PHARMACEUTICS, 2022;
FI: 6,525; Q1
Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers..
BMC MEDICAL GENOMICS, 2022;
FI: 3,622; Q2
Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells
BIOMACROMOLECULES, 2021;
FI: 6,988; D1
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?.
ANTIOXIDANTS, 2021;
FI: 6,313; D1
Development of a Biomimetic Hydrogel Based on Predifferentiated Mesenchymal Stem-Cell-Derived ECM for Cartilage Tissue Engineering
ADVANCED HEALTHCARE MATERIALS, 2021;
FI: 9,933; D1
Impact of hydroxytyrosol on stroke: tracking therapeutic response on neuroinflammation and cerebrovascular parameters using PET-MR imaging and on functional outcomes
THERANOSTICS, 2021;
FI: 11,556; D1
Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021;
FI: 3,568; Q2
Biomimetic vaccine for immunotherapy of triple-negative breast cancer
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI24 / 01282
Execution time: 01/01/2025 - 31/12/2027
IP: SERGIO GRANADOS MAIN
Proof-of-concept for a new bimodal cancer nanovaccine to potentiate immunotherapy
Funder: AECC FOUNDATION
File number: IDEAS234367GRAN
Execution time: 01/12/2023 - 30/11/2025
IP: SERGIO GRANADOS MAIN
Hybrid nanoparticles of immune cells and cancer stem cells for targeted therapy of triple negative breast cancer.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: INTRAIBS-2021-09
Execution time: 05/02/2022 - 04/02/2023
Evaluation of response to advanced therapies and conventional treatments and use as CAR-T-Cell activator of tumor exosomes from metastatic breast cancer.
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PECART-0207-2020
Execution time: 28/10/2021 - 28/10/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer.
Funder: SOLTI
Type of test: CLINICAL RESEARCH WITH MEDICAL DEVICES
Execution time: 16/10/24 - 30/12/28
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Eribulin's Real-Life Perspectives: Efficacy and Safety in Her2-Negative Metastatic Breast Cancer
Funder: SEVILLE HEALTH RESEARCH MANAGEMENT FOUNDATION
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 05/06/2024 - 30/09/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Persistence and outcomes of abemaciclib in patients with early breast cancer in clinical practice in Spain: the ABSIDE-S study.
Funder: OUTCOMES´10 SLU
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 26/04/2024 - 30/12/2027
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A randomized, open-label, phase III study of saruparib (AZD5305) plus camizestrant versus physician-selected CDK4/6 inhibitor plus hormonal therapy or plus camizestrant for the first-line treatment of patients with hormone receptor-positive, HER2-negative (0, 1+, 2+ by IHC/no amplification by ISH) advanced breast cancer with BRCA1, BRCA2, or PALB2 mutations (EvoPARBreast 01)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/09/2024 - 24/10/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, open-label, randomized trial of osimertinib with or without datopotamab deruxtecan (Dato-DXd) as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (TROPION-Lung14).
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/12/2024 - 30/06/2032
IP: SILVIA SEQUERO LOPEZ
A phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of zanidatamab versus trastuzumab, both in combination with physician-selected chemotherapy, for the treatment of participants with HER2-positive metastatic breast cancer who have progressed after or are intolerant to prior treatment with trastuzumab-deruxtecan. EmpowHER
Funder: JAZZ PHARMACEUTICAL INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 31/10/2024 - 28/02/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A randomized, double-blind, placebo-controlled phase III study of elacestrant in combination with everolimus versus elacestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with an ESR1 mutation who have previously received hormone therapy and CDK4/6 inhibitor therapy (ADELA Study).
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 08/11/2024 - 31/08/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase 3, open-label, randomized trial of datopotamab deruxtecan (Dato-DXd) with or without durvalumab compared with investigator's choice of chemotherapy (paclitaxel, nabpaclitaxel, or gemcitabine + carboplatin) in combination with pembrolizumab in patients with PD-L1-positive, locally recurrent, inoperable, or metastatic triple-negative breast cancer. (TROPION-Breast05)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 22/11/2024 - 16/05/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase 3, multicenter, randomized, open-label interventional study of pf-07220060 in combination with fulvestrant compared to investigator-selected therapy in participants 18 years of age and older with hormone receptor-positive, HER2 receptor-negative advanced/metastatic breast cancer whose disease has progressed after prior cdk 4/6 inhibitor-based therapy.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/07/2024 - 30/06/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase III, randomized, multicenter, open-label study to evaluate DB-1303 versus investigator-chosen chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) metastatic breast cancer whose cancer has progressed on endocrine therapy (DYNASTY-Breast02)
Financier: IQVIA RDS SPAIN SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/10/2024 - 30/10/2027
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase III, randomized, placebo-controlled, double-blind clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with hormone receptor-positive stage 0 to 3 breast cancer receiving adjuvant endocrine therapy.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 24/10/2024 - 30/10/2027
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A randomized, double-blind, phase III study of tiragolumab plus atezolizumab compared to placebo plus atezolizumab in participants with completely resected, stage IIb, IIIa, or IIIb selective, pd-l1 positive non-small cell lung cancer who have received platinum-based adjuvant chemotherapy.
Financier: ROCHE FARMA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/02/2024 - 30/04/2039
IP: SILVIA SEQUERO LOPEZ
Elacestrant for the treatment of patients with ER+/HER2– relapsed ctDNA breast cancer (TREAT ctDNA)
Funder: SOLTI
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 21/03/2024 - 30/07/2032
IP: ISABEL BLANCAS LOPEZ-BARAJAS
CAMBRIA-2: A phase III, open-label, randomized study to evaluate the efficacy and safety of camizestrant (AZD9833, a next-generation oral selective estrogen receptor degrader) versus standard hormonal therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment in patients with ER+/HER2- early stage breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional therapy and are free of evidence of disease.
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 15/02/2024 - 28/02/2038
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase 3, randomized, open-label, multicenter study of ARV-471 (PF-07850327) versus fulvestrant in participants with estrogen receptor-positive, HER2-negative advanced breast cancer whose disease has progressed after prior endocrine therapy for advanced disease (VERITAC-2).
Funder: PPD Research Services LLC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 04/03/2024 - 30/05/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase III, open-label, randomized trial of neoadjuvant datopotamab deruxtecan (Dato-DXd) in combination with durvalumab followed by adjuvant durvalumab with or without chemotherapy versus neoadjuvant pembrolizumab in combination with chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy for the treatment of adult patients with previously untreated triple-negative or hormone receptor-low/HER2-negative breast cancer (D926QC00001; TROPION Breast04)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/03/2024 - 09/09/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase III, open-label, randomized study to evaluate the efficacy and safety of long-term treatment with camizestrant (AZD9833, a new-generation, oral, selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) in patients with ER+/HER2- early breast cancer at intermediate or high risk of relapse who have completed definitive locoregional therapy and at least 2 years of standard adjuvant endocrine therapy without disease relapse. CAMBRIA-1
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/01/2024 - 30/05/2037
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase 2, randomized, open-label, multicenter interventional study of pf-07220060 in combination with letrozole versus letrozole monotherapy as neoadjuvant treatment in postmenopausal women aged 18 years or older with hormone receptor-positive, HER2-negative breast cancer.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 13/08/2024 - 30/12/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A phase II, open-label, single-arm study of osimertinib as induction therapy prior to CRT and osimertinib maintenance therapy in patients with unresectable stage III non-small cell lung cancer positive for epidermal growth factor receptor (EGFR) mutations (NEOLA).
Funder: FORTREA INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 16/02/2024 - 30/09/2028
IP: SILVIA SEQUERO LOPEZ
Phase II study of Trastuzumab-Deruxtecan (TDXd; DS-8201a) in patients with HER2-low-level breast cancer with newly diagnosed or progressing brain metastases (TUXEDO-4 Study).
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 03/04/2024 - 30/12/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
A multicenter, open-label, single-arm phase II trial evaluating maintenance of trastuzumab and pertuzumab after trastuzumab deruxtecan induction therapy for patients with HER2-positive, locally recurrent or metastatic unresectable breast cancer (DEMETHER).
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 11/04/2024 - 30/09/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
“A phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the DNA polymerase Theta inhibitor, ART6043, administered orally as monotherapy and in combination to patients with advanced or metastatic solid tumors
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 02/12/2024 - 30/06/2027
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized, open-label phase III study to evaluate the efficacy and safety of giraredestrant in combination with phesgo compared to phesgo after induction treatment with phesgo + taxane in patients with locally advanced or metastatic breast cancer.
Financier: ROCHE FARMA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 15/11/2023 - 30/12/2032
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Ambispective, non-interventional, multiple cohort study to evaluate the management of osimertinib treatment in patients with non-small cell lung cancer with EGFR mutations under real-life conditions in Spain. OSIREAL
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/09/2023 - 30/07/2029
IP: SILVIA SEQUERO LOPEZ
Randomized controlled and single-blind clinical trial in women with breast cancer and axillary lymphadenectomy, to evaluate the effectiveness of Hemopatch® in reducing post-surgical serous drainage
Funder: TOLEDO ASSOCIATION OF BREAST SURGEONS
Type of test: CLINICAL RESEARCH WITH PROD. SANIT.
Execution time: 08/03/2023 - 30/12/2023
IP: TANIA GALLART ARAGON
Prospective analysis of biomarkers in patients with advanced or metastatic RH+/HER2- breast cancer treated with sacituzumab govitecan. ACROSS-TROP2 TRIAL
Funder: SOLTI
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 05/10/2023 - 30/08/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III post-neoadjuvant study evaluating Sacituzumab Govitecan, an antibody conjugate, in patients with HER2-negative primary breast cancer at high risk of relapse after standard neoadjuvant treatment – SASCIA
Funder: GERMAN BREAST GBG FORSCHUNGSGESELLSCHAFT GMBH
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/03/2023 - 30/03/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of the HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in subjects with residual disease or high-risk HER2/neu-positive pCR after neoadjuvant treatment
Funder: GREENWICH LIFESCIENCES, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/09/2023 - 30/10/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Open-label, randomized, non-comparative Phase 2 study of ARV-471 or anastrozole in postmenopausal women with ER+/HER2– breast cancer in the neoadjuvant setting.TRIO048. GEICAM/2021-07
Financier: ARVINAS ESTROGEN RECEPTOR INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 27/01/2023 - 30/06/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II study of trastuzumab deruxtecan in the first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer (MBC) considered resistant to trastuzumab + pertuzumab + taxane due to early relapse.
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/08/2023 - 30/03/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II study for advanced metaplastic breast cancer with PI3KCA/PTEN alteration treated with MEN1611 monotherapy or in combination with eribulin. –SABINA study
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/02/2023 - 31/12/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Preoperative window of opportunity study with giraredestrant (GDC-9545) or tamoxifen in premenopausal women with early-stage breast cancer (EBC) ER[+]/HER2[-] and Ki67=10%”. – The EMPRESS study
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 26/06/2023 - 30/09/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Preliminary efficacy study to evaluate the efficacy of treatments by controlling minimal residual disease with ctDNA in the population with RH-positive/HER2-negative early breast cancer. MIRADOR
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 03/04/2023 - 30/04/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Retrospective, observational, multicenter, real-life study of dostarlimab in patients with recurrent endometrial cancer with mismatch repair (MMR) deficiency or high microsatellite instability. DORA study
Funder: SPANISH OVARIAN CANCER RESEARCH GROUP
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 08/02/2023 - 30/12/2023
IP: MARTA LEGEREN ALVAREZ
Observational, multicenter, international study to understand the effect of the COVID-19 pandemic on the treatment of patients with unresectable stage III non-small cell lung carcinoma (NSCLC)
Funder: ASTRAZENECA UK LTD
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 26/01/2022 - 30/12/2022
IP: SILVIA SEQUERO LOPEZ
Evaluation of outcomes of patients with metastatic or locally advanced breast cancer treated with abemaciclib who participate in the Patient Support Program in Spain. 2019-9039 VERZENIOS
Financier: LILLY, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/08/2022 - 31/03/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational study to monitor the activity of patients with lung cancer and evaluate their functional status using mobile devices. MAGNIFYING-01
Financier: ROCHE FARMA, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 07/11/2022 - 31/05/2023
IP: SILVIA SEQUERO LOPEZ
Phase II clinical trial of the combination of palbociclib, trastuzumab, and endocrine therapy, in patients with previously treated HER2-positive locally advanced or metastatic breast cancer. PATRICIA II. GEICAM/2018-07
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 24/02/2022 - 28/02/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational and multinational study to characterize the use and efficacy of abemaciclib in patients with metastatic breast cancer.
Financier: LILLY, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 23/09/2022 - 30/12/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Financier: LILLY, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 08/12/2022 - 30/03/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II clinical trial of AMG510 (SOTORASIB) in patients with unresectable stage III non-small cell lung cancer (NSCLC) with kras p.G12 mutation ineligible for treatment with chemoradiotherapy. MERIT-lung
Funder: GECP FOUNDATION
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/02/2022 - 30/09/2027
IP: SILVIA SEQUERO LOPEZ
Phase II, open-label, multicenter trial to evaluate the efficacy and safety of nal-IRI in patients with HER2-negative breast cancer with progressive brain metastases
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/11/2022 - 30/04/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative Breast Cancer.
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 05/12/2022 - 31/12/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized, Open-Label Phase 3 Trial of Datopotamab Deruxtecan (Dato-DXd) Compared to Investigator's Choice Chemotherapy in Patients With Inoperable Locally Recurrent or Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for PD Inhibitor Therapy -1/PD-L1 in front line (TROPION-Breast02)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 24/05/2022 - 30/12/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II, randomized, open-label, 2-arm treatment study of abemaciclib in combination with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line treatment in patients with breast cancer HR positive/HER2 negative locally advanced and unresectable or metastatic with criteria for aggressive disease (ABIGAIL)
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 29/12/2021 - 30/06/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase 3, randomized, double-blind study to compare the efficacy and safety of niraparib versus placebo in participants with HER2-negative breast cancer with a BRCA mutation or triple-negative breast cancer, with molecular disease based on the presence of tumor DNA circulating after definitive therapy (ZEST).
Funder: GLAXOSMITHKLINE, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/07/2022 - 30/06/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, double-blind, placebo-controlled, randomized, multicenter, international trial with Durvalumab plus Oleclumab and Durvalumab plus Monalizumab in patients with locally advanced (stage III) and unresectable non-small cell lung cancer (NSCLC) who have not progressed after a definitive concomitant platinum-based chemoradiotherapy (PACIFIC-9).
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/03/2022 - 30/10/2030
IP: SILVIA SEQUERO LOPEZ
Phase 1b/2a, Basket-type Study, to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of the combination therapy of Tafasitamab, anti-CD19 monoclonal antibody, and Parsaclisib (PI3Kd Inhibitor), in Adult Patients with Non-Hodgkin's Lymphoma or Leukemia Chronic Lymphocytic Disease in Relapse or Refractory (topMIND)
Financer: INCYTE CORPORATION
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 28/06/2022 - 30/03/2023
IP: SILVIA SEQUERO LOPEZ
Phase II, randomized study to evaluate the incidence of discontinuation due to Diarrhea in the first 3 cycles of treatment in patients with HER2-positive (HER2+), Hormone Receptor-positive (HR+) Early Breast Cancer, treated with Neratinib plus Loperamide versus Neratinib with initial dose escalation plus Loperamide (as needed) versus Neratinib plus Loperamide plus Colesevelam. DIANER Study
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/07/2022 - 30/06/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of adjuvant giredestrant compared to physician-selected adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer. LEAD
Financier: F. HOFFMANN-LA ROCHE LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/02/2022 - 30/03/2034
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase 1b/2, open-label, randomized, non-comparative study of nadunolimab in combination with gemcitabine and carboplatin in patients with advanced triple-negative breast cancer. “TRIFOUR Studio”
Financier: CANTARGIA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/04/2022 - 30/08/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational study in patients with HR+ / HER2- metastatic breast cancer treated with Abemaciclib. Review of medical records
Financer: LILLY, SAU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 19/03/2021 - 01/04/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Encorafenib plus binimetinib in patients with real-life treated locally advanced, unresectable, or metastatic BRAFV600-mutated melanoma in Spain: a multicenter, retrospective, non-interventional study. BECARE
Funding: SPANISH MULTIDISCIPLINARY MELANOMA GROUP (GEM)
Type of test: REST OF OBSERVATIONAL STUDIES WITH MEDICINES
Execution time: 28/07/2021 - 30/06/2022
IP: SILVIA SEQUERO LOPEZ
Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer. RIBOLARIS
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 17/12/2021 - 28/02/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Study to evaluate the effect of metformin in the prevention of hyperglycemia in patients with HR positive/HER2 negative advanced breast cancer and PIK3ca mutation treated with alpelisib and endocrine therapy. Metallic studio.
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 23/03/2021 - 30/10/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, randomized, open-label, controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2-positive primary breast cancer presenting with residual invasive disease
Funder: DAIICHI-SANKYO, INC.
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 16/04/2021 - 30/03/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, open-label study of ribociclib compared to palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched advanced breast cancer – HARMONIA trial
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 18/11/2021 - 28/02/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant treatment with atezolizumab or placebo and trastuzumab emtansine in HER2+-positive breast cancer at high risk of recurrence of
Financier: ROCHE FARMA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/01/2021 - 31/12/2031
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in previously treated patients with HER2+ advanced breast cancer with PIK3CA mutation. “ALPHABET STUDIO”
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 14/09/2021 - 30/05/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
EMBER-3: Phase 3, Randomized, Open-Label Study Comparing LY3484356 With Investigator's Choice Hormonal Therapy in Patients With Estrogen Receptor Expressing, Locally Advanced or Metastatic Breast Cancer Without Envelope
Financer: LILLY, SAU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 31/05/2021 - 30/03/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
eMonarcHER: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Abemaciclib With Standard Adjuvant Hormone Therapy In Participants With HR+, HER-2+, High-Risk, Nodal-Involved Breast Cancer Who
Financer: LILLY, SAU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 01/09/2021 - 30/10/2031
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Prediction of Sensitivity to Olaparib in Patients With Unresectable or Metastatic Locally Advanced HER2-Negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mutations or Low RAD51 Levels: RADIOLA ASSAY
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/11/2021 - 28/02/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Chemotherapy-Free Strategy Based on Complete Pathologic Response With Subcutaneous Trastuzumab-Pertuzumab and T-DM1 in Early-Stage HER2-Positive Breast Cancer (PHERGAIN-2)
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/09/2021 - 30/12/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
ATREZZO: Phase II clinical trial with two parallel cohorts in patients with negative estrogen receptors or non-luminal disease according to PAM50, Treatment with atezolizumab in combination with trastuzumab and vinorelbine in advanced breast cancer/
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 13/01/2021 - 28/02/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II clinical trial to evaluate the efficacy and safety of first-line treatment with atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer. ATTRACTIVE
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/05/2021 - 30/03/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
